Clinical Study of PEG Bowel Preparation in Appendectomy Patients
Colonoscopy is a necessary item of physical examination for colorectal cancer. For high-risk groups, annual physical examination is the most effective way of early prevention; At present, a large amount of polyethylene glycol (PEG2000 - 4000) is often used as laxative and lubricant in colonoscopy. However, the widespre
| Condition(s) | Appendicitis, Appendicitis Acute |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Colonoscopy is a necessary item of physical examination for colorectal cancer. For high-risk groups, annual physical examination is the most effective way of early prevention; At present, a large amount of polyethylene glycol (PEG2000 - 4000) is often used as laxative and lubricant in colonoscopy. However, the widespread use of PEG may cause long-term and irreversible damage to intestinal microorganisms and bring great hidden dangers to health. The appendix has long been regarded as a redundant organ in evolution. The incidence of appendicitis ranks first in surgical acute abdomen. Traditionally, once acute appendicitis is diagnosed, it is usually treated with appendectomy. However, recent studies have revealed that appendectomy may be associated with psychiatric diseases, colorectal cance |
| Who can participate | Inclusion Criteria: * Aged 18-75 years. * Scheduled to undergo colonoscopy. * Generally healthy without major organ diseases. 1. For appendectomy group: history of appendectomy or right hemicolectomy (including appendectomy). 2. For control group: no history of appendectomy or right hemicolectomy. Exclusion Criteria: * Allergy or intolerance to PEG laxatives. * Pregnant or lactating women. * Mental disorders. * Use of antibiotics within 6 months prior to study enrollment. 1. Contraindications to colonoscopy (e.g., severe cardiopulmonary insufficiency). 2. For control group only: presence of organic diseases. |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Huaping Xie |
| Locations | Wuhan, Hubei, China |
| Start date | 2024-02-23 |
| NCT ID | NCT07478029 |
| Official listing | https://clinicaltrials.gov/study/NCT07478029 |